PRECIGEN, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
PRECIGEN, INC. (PGEN) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-04
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was -$111.50M.
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$139.52M.
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $0.00.
- PRECIGEN, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | -$111.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | -$111.50M derived: sum of 3 quarters · filed 2026-05-13 | -$107.04M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$111.50M derived: sum of 2 quarters · filed 2026-03-25 | -$107.04M derived: sum of 3 quarters · filed 2026-08-04 | -$139.52M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$111.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$107.04M derived: sum of 2 quarters · filed 2026-08-04 | -$139.52M 10-Q · filed 2025-11-13 | -$139.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$28.02M 10-Q · filed 2026-08-04 | -$28.02M derived: sum of 3 quarters · filed 2026-08-04 | -$28.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$32.48M 10-Q · filed 2026-05-13 | -$32.48M derived: sum of 2 quarters · filed 2026-05-13 | -$32.48M derived: sum of 3 quarters · filed 2026-05-13 | -$32.48M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-25 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | -$106.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$106.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$106.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |